Stempoint Capital’s LB Pharmaceuticals LBRX Stock Holding History

Stempoint Capital’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.23M	Buy	+50,000	New	+$1.15M	0.24%	63

Other funds holding LBRX

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Spruce Street Capital New York $416M AUM

JP Morgan Chase

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Stempoint Capital's LBRX Position: Q1 2026 in Review

Stempoint Capital opened a new position in LB Pharmaceuticals (LBRX) in Q1 2026: 50,000 shares worth $1.23M. The stake represents 0.24% of the portfolio and ranks #63 among its holdings.

77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

Stempoint Capital held 50,000 shares of LB Pharmaceuticals worth $1.23M as of Q1 2026.
LB Pharmaceuticals was a new Stempoint Capital position in Q1 2026.
LB Pharmaceuticals made up 0.24% of Stempoint Capital's portfolio in Q1 2026, its #63 holding.
77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.